Home › Compare › EVGPF vs ABBV
EVGPF yields 1233.81% · ABBV yields 3.06%● Live data
📍 EVGPF pulled ahead of the other in Year 1
Combined, EVGPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EVGPF + ABBV for your $10,000?
Evergrande Property Services Group Limited, an investment holding company, provides property management services in the People's Republic of China. The company manages a portfolio of properties, including mid- to high-end residential properties, offices buildings, commercial properties, theme and industrial parks, healthcare complexes, themed towns, schools, etc. It offers property management services, including butler, security, cleaning and greening, and repair and maintenance services to residents, property developers, and tenants of non-residential properties. The company also provides value-added services, such as preliminary property management services comprising construction site and sales office management, and consulting services; pre-delivery services consisting of properties cleaning and inspecting; properties repair and maintenance services; and property transaction assistance services to non-property owners. In addition, it offers community value-added services that include community operation services, including group purchase activities, community space operations, etc.; community assets management services that include parking space leasing, real estate agency, sports and entertainment complex operation, etc.; and community living services, such as housekeeping, home renovation, etc., as well as recreation center operations services. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China. Evergrande Property Services Group Limited is a subsidiary of CEG Holdings (BVI) Limited.
Full EVGPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.